Cardiome Pharma (CRME) Misses Q2 EPS by 22c

Cardiome Pharma (NASDAQ: CRME) reported Q2 EPS of ($0.43), $0.22 worse than the analyst estimate of ($0.21). Revenue for the quarter came in at $5.7 million versus the consensus estimate of $7.67 million.

For earnings history and earnings-related data on Cardiome Pharma (CRME) click here.

You May Also Be Interested In

• JPMorgan Upgrades Aviva Plc (AV/:LN) (AIVAF) to Overweight
• North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
• Park Dental Partners, Inc. (PARK) Tops Q2 EPS by 28c